A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 12
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- B-cell Non Hodgkin Lymphoma
- Pre B-Cell Acute Lymphoblastic Leukaemia
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03114865
- Collaborators
- Amgen
- Investigators
- Study Chair: Ivana Gojo, MD Johns Hopkins University Principal Investigator: Jonathan Webster, MD Johns Hopkins University
Get Well Soon